1B), with a significant increase in T2, T3, and T5 (56.94% 9.61%, 60.99% 8.1%, and 57.42% 9.82%
While our preferred metric is the presence of fibrinaloid microclots (measures such as D-dimer reflecting those of clot breakdown rather than clot presence [89]), these have not been carried out, so we need to look to more traditional measures of clotting potential, where similar suspicions have been raised [288,367,368,369,370], and some limited longitudinal evidence brought forward [345]
It does not create a branded finished drug, it does not trigger insurance coverage, and it does not retroactively validate marketing claims made about the compound
Not Accounting for Injection Volume A 1mL subcutaneous injection is already on the larger side